Needham & Company Maintains a 'Buy' on Pernix Therapeutics (PTX); Price Increase On Cedax Franchise Provides Solid Near-Term Buffer
Tweet Send to a Friend
Needham & Company maintains a 'Buy' on Pernix Therapeutics (NYSE: PTX) price target of $14.00.
Analyst, Elliot Wilbur, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Elliot Wilbur, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
